⌕
Biomarin Pharmaceutical · BMRN · Nasdaq
Tenet 43 · Weak
Compare
$58.51+0.90%At closeTenet 43 · Weak
$58.51+0.52 (+0.90%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Biomarin Pharmaceutical (BMRN) Earnings Forecast

Analysts expect Biomarin Pharmaceutical (BMRN) to earn $3.03 a share in FY26, the average of 16 estimates as of Nov 16, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

FY26 consensus EPS
$3.03
16 analysts
FY27 consensus EPS
$6.43
16 analysts · low $4.16, high $7.35
EPS revisions, 31 days
−39.8%
$5.03 to $3.03
Disagreement, FY26
30.2%
high to low, $2.80 to $3.72

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 16, 2026 · we check it nightly

Analysts expect Biomarin Pharmaceutical to earn $9.25 a share in FY30, growing about 32% a year; 6 analysts publish an estimate for FY30.

Forward P/E · FY26E
19.2×
$57.99 (as of close, Nov 16, 2026) ÷ $3.03 consensus EPS
Coverage · FY26
16 · 20
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $3.03, down 38.8% in 90 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−46.6%−18.7%+9.2%FY27 −3.0%FY26 −38.8%Aug 18Nov 16
EPS30 days90 daysshown aboveSince Jul 6
FY2616 analysts▼ −39.8%$5.03 to $3.03▼ −38.8%$4.94 to $3.03▼ −38.8%$4.95 to $3.03
FY2716 analysts▼ −1.7%$6.55 to $6.43▼ −3.0%$6.63 to $6.43▼ −1.6%$6.54 to $6.43
Dec '2612 analysts▼ −52.9%$1.75 to $0.82▼ −52.8%$1.75 to $0.82▼ −52.8%$1.75 to $0.82
Mar '276 analysts24 of 30 days+0.9% so far24 of 90 days+0.9% so far▲ +0.9%$1.46 to $1.47

Contributors at both ends of the window: FY26 15 and 16. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 16, 2026 · consensus as of Nov 16, 2026

At 33.6 times earnings, its median over the last ten fiscal years, the FY27 consensus of $6.43 works out to $216 a share.

Consensus EPS · FY27
$6.43
16 analysts · low $4.16, high $7.35
Multiple · ten-year median P/E
33.6×
Median of the 7 fiscal-year P/Es, FY08 to FY25.
×
Receipt · BMRN · FY27Nov 16, 2026
Implied, a share
$216

Range on the low and high estimate: $140 to $247.

$140 low$247 high
6.43 × 33.6, to the dollar
Drag the multipleShaded: where Biomarin Pharmaceutical's P/E sat at each fiscal year end, FY08 to FY25. Each dot is one year.
14×20×30×40×50×60×
10-yr median 33.6×$216 a share

Each point on the line is a multiple, and the flag is the price it implies for FY27. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

You are paying 19.2 times the FY26 consensus for earnings the Street expects to grow about 59% a year to FY28. That is 0.3 times the growth rate.Show the multiple against its own recordHide the multiple record
Trailing P/E at each fiscal year end, FY08 to FY25 · over 7 fiscal years. The mark is the median of the last 7.
16.4× low138.1× high
33.6× median
Forward 19.2× is a different measure, so it is not placed on a trailing record. We hold no trailing multiple for this company today, so nothing marks today on the track.

How much do analysts disagree?

For FY30, estimates run from $8.77 to $9.75 around an average of $9.25, drawn by 6 analysts.

FY26E16 analysts
$2.80 to $3.72 · 30.2%
FY27E16 analysts
$4.16 to $7.35 · 49.6%
FY28E15 analysts
$4.01 to $10.92 · 90.0%
FY29E9 analysts
$8.23 to $9.15 · 10.6%
FY30E6 analysts
$8.77 to $9.75 · 10.6%

The dashed line is FY25 filed $1.80, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average.

Is next quarter a high bar or an easy one?

Analysts expect Biomarin Pharmaceutical to earn $0.82 a share in the December quarter, the average of 12 estimates. We hold no expected date for the next report. Last quarter, which ended in June, Biomarin Pharmaceutical earned $1.23 a share. Analysts had expected $0.86, so it came in 42.9% higher.

0
$−0.22
$0.82high $1.50
low $0.62
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 12 analysts
Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
$1,089.2M
15 analysts, 1,069.3 to 1,119.2 in $M · 874.6 in the same quarter a year ago

A year ago this quarter was a loss, so the change from it is not a percentage and none is printed. Last quarter's comparison is measured against the last estimate we hold for that quarter rather than the one from the night before the report, because the nearest estimate we hold for it was recorded after the company had already reported. For the March quarter, analysts expect $1.47 a share.

Does Biomarin Pharmaceutical usually beat or miss?

So far we have checked 6 quarters, of which 6 came in above the estimate we held. We add a quarter to this record each time Biomarin Pharmaceutical reports.

We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.

Before our record
Dec '23
Our record, one quarter per report
+47.5%
Mar '24reaction
−9.9%
+53.7%
Jun '24reaction
+8.0%
+3.6%
Sep '24reaction
−4.6%
+21.7%
Dec '24reaction
+4.8%
+33.0%
Mar '25reaction
−1.1%
+42.9%
Jun '25reaction
+2.7%
Sep '25left out
Dec '25left out · adjusted
Mar '26left out · adjusted
Jun '26left out · adjusted
Sep '26left out · adjusted
Dec '26not reported yet
Checked so far
6 quarters
one more every report
Beat expectations
6 of 6
full details on the Earnings tab
Share price reaction
0.0%
the average over all 6 checked quarters, one session each, timed to each release
Typical gap vs estimate
+38.0%
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Biomarin Pharmaceutical on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact. Mar '24, Jun '24, Sep '24, Dec '24, Mar '25, Jun '25 are drawn hollow: we hold no estimate for those quarters recorded strictly before the report, so it is scored against the last estimate we hold rather than the night-before one.

The Street expects sales to grow 15.2% in FY27 and EPS 112.5%. Little of it is sales: the net margin moves from 15.3% to 28.0%, and the implied share count from about 196M to 194M, so these numbers assume the count keeps falling.Show the decomposition and the margin ladderHide the decomposition
FY27 EPS growth, in points
Revenue growth+15.2
Net margin change+95.1
Share count change+2.2
EPS growth+112.5
Legs are rounded to a tenth of a point and the largest remainder carries the difference, so they add to the total. Implied shares = consensus net income ÷ consensus EPS, a direction rather than a decimal.
16 analysts publish an EPS estimate for FY26 and 20 publish revenue. Coverage thins with distance: 6 EPS estimates for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
2016
FY26E
2016
FY27E
1915
FY28E
99
FY29E
156
FY30E
The FY26 panel has held 16 analysts every night since our record of it began on Jul 6, 2026.

The full consensus, year by year

Consensus as of Nov 16, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
1.93.95.9historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 20 revenue estimates for FY26, 15 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
0.145.7411.33historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 16 EPS estimates for FY26, 6 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed3.2—1.80————as filedn/m
FY26E3.93.8 to 3.9▲20.1%a3.032.80 to 3.72▲68.2%a0.80.60.2020 · 1619.2×
FY27E4.54.2 to 4.7▲15.2%6.434.16 to 7.35▲112.5%1.61.20.1920 · 169.0×
FY28E4.84.5 to 5.2▲8.5%7.684.01 to 10.92▲19.4%1.91.50.1919 · 157.5×
FY29E5.25.0 to 5.4n/cb8.688.23 to 9.15n/cb2.21.70.209 · 96.7×
FY30E5.55.3 to 5.7n/cb9.258.77 to 9.75▲6.6%2.41.80.2015 · 66.3×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 16 EPS estimates for FY26, 20 for revenue. Not investment advice.

What do analysts expect Biomarin Pharmaceutical to earn in FY26?

Analysts expect Biomarin Pharmaceutical to earn $3.03 a share in FY26, the average of 16 estimates as of Nov 16, 2026.

What is Biomarin Pharmaceutical's earnings forecast for FY27?

The FY27 consensus for Biomarin Pharmaceutical is $6.43 a share from 16 analysts, with a low of $4.16 and a high of $7.35, as of Nov 16, 2026.

Have analysts raised Biomarin Pharmaceutical's earnings estimates?

Biomarin Pharmaceutical's FY26 EPS consensus fell 38.8% in 90 days, from $4.94 to $3.03, as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.